Arthrex 的新型 NanoNeedle Scope 2.0 已获得 FDA 批准，用于儿童，通过侵入性较小的高分辨率成像帮助治疗 13 岁儿童的肩部损伤。 Arthrex's new NanoNeedle Scope 2.0, FDA-cleared for kids, helped treat a 13-year-old’s shoulder injury with less invasive, high-resolution imaging.

美国食品和药物管理局批准的微创影像装置NanoNeedleTM Scope 2.0 已经推出, 首次在一个13岁的棒球运动员身上进行临床应用. Arthrex has launched the NanoNeedle™ Scope 2.0, a minimally invasive imaging device cleared by the FDA for pediatric orthopedic use, marking its first clinical application in a 13-year-old baseball player with a labrum tear. 1.9毫米的范围有一个720×720传感器,其分辨率为224%以上,是其前身像素密度的三倍以上,能够通过小切口实现高质量的可视化。 The 1.9 mm scope features a 720 × 720 sensor, delivering 224% higher resolution and over three times the pixel density of its predecessor, enabling high-quality visualization through tiny incisions. 它设计用于开发小型接合点,减少组织损伤、疼痛和恢复时间,同时尽量减少液体使用和软体损伤。 Designed for small, developing joints, it reduces tissue damage, pain, and recovery time while minimizing fluid use and cartilage injury. 作为 Synergy Vision™ 系统的一部分，该无菌设备为传统关节镜检查提供了一种侵入性较小的替代方案。 Part of the Synergy Vision™ system, the sterile device offers a less invasive alternative to traditional arthroscopy. 外科医生赞扬其形象清晰度以及推进超小入侵外科手术的潜力。 Surgeons praise its image clarity and potential to advance ultra-minimally invasive surgery. 预计2025年晚些时候将有一个移动版本。 A mobile version is expected later in 2025.